87 related articles for article (PubMed ID: 25334011)
1. Dynamic principle for designing antagonistic/agonistic molecules for EphA4 receptor, the only known ALS modifier.
Qin H; Lim LZ; Song J
ACS Chem Biol; 2015 Feb; 10(2):372-8. PubMed ID: 25334011
[TBL] [Abstract][Full Text] [Related]
2. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.
Ling KK; Jackson M; Alkam D; Liu D; Allaire N; Sun C; Kiaei M; McCampbell A; Rigo F
Neurobiol Dis; 2018 Jun; 114():174-183. PubMed ID: 29518482
[TBL] [Abstract][Full Text] [Related]
3. Potent and Selective EphA4 Agonists for the Treatment of ALS.
Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M
Cell Chem Biol; 2017 Mar; 24(3):293-305. PubMed ID: 28196613
[TBL] [Abstract][Full Text] [Related]
4. NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.
Baggio C; Kulinich A; Dennys CN; Rodrigo R; Meyer K; Ethell I; Pellecchia M
J Med Chem; 2021 Aug; 64(15):11229-11246. PubMed ID: 34293864
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
6. Structural, stability, dynamic and binding properties of the ALS-causing T46I mutant of the hVAPB MSP domain as revealed by NMR and MD simulations.
Lua S; Qin H; Lim L; Shi J; Gupta G; Song J
PLoS One; 2011; 6(11):e27072. PubMed ID: 22069488
[TBL] [Abstract][Full Text] [Related]
7. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.
Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB
Biochem J; 2012 Jul; 445(1):47-56. PubMed ID: 22489865
[TBL] [Abstract][Full Text] [Related]
8. High-content analysis of proapoptotic EphA4 dependence receptor functions using small-molecule libraries.
Nelersa CM; Barreras H; Runko E; Ricard J; Shi Y; Glass SJ; Bixby JL; Lemmon VP; Liebl DJ
J Biomol Screen; 2012 Jul; 17(6):785-95. PubMed ID: 22492230
[TBL] [Abstract][Full Text] [Related]
9. Are we using the right pharmacological tools to target EphA4?
Tognolini M; Incerti M; Lodola A
ACS Chem Neurosci; 2014 Dec; 5(12):1146-7. PubMed ID: 25405504
[TBL] [Abstract][Full Text] [Related]
10. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS.
Krishnaraj RN; Kumari SS; Mukhopadhyay SS
J Recept Signal Transduct Res; 2016; 36(1):67-71. PubMed ID: 26053508
[TBL] [Abstract][Full Text] [Related]
12. Protein dynamics at Eph receptor-ligand interfaces as revealed by crystallography, NMR and MD simulations.
Qin H; Lim L; Song J
BMC Biophys; 2012 Jan; 5():2. PubMed ID: 22277260
[TBL] [Abstract][Full Text] [Related]
13. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of Nanobodies targeting the EphA4 receptor.
Schoonaert L; Rué L; Roucourt B; Timmers M; Little S; Chávez-Gutiérrez L; Dewilde M; Joyce P; Curnock A; Weber P; Haustraete J; Hassanzadeh-Ghassabeh G; De Strooper B; Van Den Bosch L; Van Damme P; Lemmens R; Robberecht W
J Biol Chem; 2017 Jul; 292(27):11452-11465. PubMed ID: 28526745
[TBL] [Abstract][Full Text] [Related]
15. Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.
Guo FY; Lesk AM
Proteins; 2014 Mar; 82(3):349-53. PubMed ID: 24105818
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state.
Farenc C; Celie PH; Tensen CP; de Esch IJ; Siegal G
FEBS Lett; 2011 Nov; 585(22):3593-9. PubMed ID: 22036717
[TBL] [Abstract][Full Text] [Related]
17. EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes.
Dennys C; Baggio C; Rodrigo R; Roussel F; Kulinich A; Heintzman S; Fox A; Kolb SJ; Shaw PJ; Ethell IM; Pellecchia M; Meyer KC
iScience; 2022 Sep; 25(9):104877. PubMed ID: 36034213
[TBL] [Abstract][Full Text] [Related]
18. Eph receptor tyrosine kinases regulate astrocyte cytoskeletal rearrangement and focal adhesion formation.
Puschmann TB; Turnley AM
J Neurochem; 2010 May; 113(4):881-94. PubMed ID: 20202079
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors.
Parmentier-Batteur S; Finger EN; Krishnan R; Rajapakse HA; Sanders JM; Kandpal G; Zhu H; Moore KP; Regan CP; Sharma S; Hess JF; Williams TM; Reynolds IJ; Vacca JP; Mark RJ; Nantermet PG
J Neurochem; 2011 Sep; 118(6):1016-31. PubMed ID: 21736568
[TBL] [Abstract][Full Text] [Related]
20. Localization of EphA4 in axon terminals and dendritic spines of adult rat hippocampus.
Tremblay ME; Riad M; Bouvier D; Murai KK; Pasquale EB; Descarries L; Doucet G
J Comp Neurol; 2007 Apr; 501(5):691-702. PubMed ID: 17299751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
